← Back to Clinical Trials
Recruiting NCT00005095

NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00005095
Status Recruiting
Phase
Sponsor Northwestern University
Condition Cervical Cancer
Study Type OBSERVATIONAL
Enrollment 6,000 participants
Start Date 2000-03
Primary Completion 2030-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Ca-125screening questionnaire administrationSurgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 6,000 participants in total. It began in 2000-03 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

Eligibility Criteria

DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Considered to be at increased risk for developing ovarian cancer, as defined by one of the following: * Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer * Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor * A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer * Increased risk as deemed by a certified genetic counselor * Undergoing surgery for a gynecologic condition, including any of the following: * Diagnosis of a reproductive cancer * Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts) * Highly suspicious adnexal mass * Risk-reducing prophylactic oophorectomy PATIENT CHARACTERISTICS: Age * Between the ages of 18 and 80

Contact & Investigator

Central Contact

Takelia Walker

✉ takelia-watson@northwestern.edu

📞 3125034802

Principal Investigator

Lee P. Shulman, MD

STUDY CHAIR

Robert H. Lurie Cancer Center

Frequently Asked Questions

Who can join the NCT00005095 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 80 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00005095 currently recruiting?

Yes, NCT00005095 is actively recruiting participants. Contact the research team at takelia-watson@northwestern.edu for enrollment information.

Where is the NCT00005095 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT00005095 clinical trial?

NCT00005095 is sponsored by Northwestern University. The principal investigator is Lee P. Shulman, MD at Robert H. Lurie Cancer Center. The trial plans to enroll 6,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology